{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:39:39Z","timestamp":1788413979767,"version":"build-2803163510"},"reference-count":57,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Benzodiazepines (BZDs) are among the most widely prescribed psychotropic drugs in modern healthcare, primarily used as anxiolytics, hypnotics, anticonvulsants, and muscle relaxants. However, rising global consumption and prolonged use raise significant concerns about safety and dependence. Recent studies report that up to 35.8% of patients continue BZD therapy beyond three months, with long-term use observed in over 5% of the general population. These patterns highlight the need for evidence-based strategies to improve prescribing practices. BZDs are recommended primarily for short-term management of severe anxiety or transient insomnia, typically limited to 2\u20134 weeks. In anxiety disorders, SSRIs and SNRIs are first-line treatments. BZD use is particularly discouraged in older adults due to increased risks of cognitive impairment, falls, and dependence. Rational prescribing requires individualized assessment, minimal effective dosing, gradual withdrawal protocols, and patient education. Enhanced regulatory oversight and improved access to psychotherapy are essential for safer benzodiazepine use.<\/jats:p>","DOI":"10.3390\/healthcare14101392","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:31Z","timestamp":1779196291000},"page":"1392","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rational Use of Benzodiazepines in Modern Healthcare: Evidence-Based Strategies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8464-4924","authenticated-orcid":false,"given":"Janko","family":"Samard\u017ei\u0107","sequence":"first","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Tandon","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Brankovi\u0107","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","article-title":"The History of Benzodiazepines","volume":"28","author":"Wick","year":"2013","journal-title":"Consult. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Samardzic, J. (2018). GABA and Glutamate\u2014New Developments in Neurotransmission Research, InTech.","DOI":"10.5772\/intechopen.68762"},{"key":"ref_3","first-page":"214","article-title":"Benzodiazepine Pharmacology and Central Nervous System-Mediated Effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2105\/AJPH.2016.303061","article-title":"Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996\u20132013","volume":"106","author":"Bachhuber","year":"2016","journal-title":"Am. J. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Luka\u010di\u0161inov\u00e1, A., Reissigov\u00e1, J., Ortner-Had\u017eiabdi\u0107, M., Brkic, J., Okuyan, B., Volmer, D., Tadi\u0107, I., Modamio, P., Mari\u00f1o, E.L., and Tachkov, K. (2024). Prevalence, Country-Specific Prescribing Patterns and Determinants of Benzodiazepine Use in Community-Residing Older Adults in 7 European Countries. BMC Geriatr., 24.","DOI":"10.1186\/s12877-024-04742-7"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gosmann, N.P., Costa, M.d.A., Jaeger, M.d.B., Motta, L.S., Frozi, J., Spanemberg, L., Manfro, G.G., Cuijpers, P., Pine, D.S., and Salum, G.A. (2021). Selective Serotonin Reuptake Inhibitors, and Serotonin and Norepinephrine Reuptake Inhibitors for Anxiety, Obsessive-Compulsive, and Stress Disorders: A 3-Level Network Meta-Analysis. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003664"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Santana Ayala, J.R., Alberto Armas, D., Hern\u00e1ndez Garc\u00eda, V., Aguirre-Jaime, A., Guti\u00e9rrez, \u00c1.J., Paz-Montelongo, S., Hardisson de la Torre, A., and Rubio Armend\u00e1riz, C. (2025). Benzodiazepine (BZD) Use and Patient Safety: Opportunities for Community Pharmacy Involvement in the Management of Drug Interactions. Pharmacy, 13.","DOI":"10.3390\/pharmacy13060181"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gress, T., Miller, M., Meadows, C., and Neitch, S.M. (2020). Benzodiazepine Overuse in Elders: Defining the Problem and Potential Solutions. Cureus, 12.","DOI":"10.7759\/cureus.11042"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Brandt, J., Bressi, J., L\u00ea, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., and Wright, S. (2024). Prescribing and Deprescribing Guidance for Benzodiazepine and Benzodiazepine Receptor Agonist Use in Adults with Depression, Anxiety, and Insomnia: An International Scoping Review. EClinicalMedicine, 70.","DOI":"10.1016\/j.eclinm.2024.102507"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ghit, A., Assal, D., Al-Shami, A.S., and Hussein, D.E.E. (2021). GABAA Receptors: Structure, Function, Pharmacology, and Related Disorders. J. Genet. Eng. Biotechnol., 19.","DOI":"10.1186\/s43141-021-00224-0"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Goldschen-Ohm, M.P. (2022). Benzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective. Biomolecules, 12.","DOI":"10.3390\/biom12121784"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41594-023-01133-1","article-title":"The Molecular Basis of Drug Selectivity for A5 Subunit-Containing GABAA Receptors","volume":"30","author":"Kasaragod","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vega Alanis, B.A., Iorio, M.T., Silva, L.L., Bampali, K., Ernst, M., Schn\u00fcrch, M., and Mihovilovic, M.D. (2020). Allosteric GABAA Receptor Modulators-A Review on the Most Recent Heterocyclic Chemotypes and Their Synthetic Accessibility. Molecules, 25.","DOI":"10.3390\/molecules25040999"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1590\/1516-4446-2020-1651","article-title":"Dependence on Hypnotics: A Comparative Study between Chronic Users of Benzodiazepines and Z-Drugs","volume":"44","author":"Curado","year":"2022","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bardhi, K., Coates, S., Chen, G., and Lazarus, P. (2024). Cannabinoid-Induced Stereoselective Inhibition of R-S-Oxazepam Glucuronidation: Cannabinoid-Oxazepam Drug Interactions. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020243"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hsu, T.-W., Chen, H.-M., Chen, T.-Y., Chu, C.-S., and Pan, C.-C. (2021). The Association between Use of Benzodiazepine Receptor Agonists and the Risk of Obstructive Sleep Apnea: A Nationwide Population-Based Nested Case-Control Study. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18189720"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tanguay Bernard, M.-M., Luc, M., Carrier, J.-D., Fournier, L., Duhoux, A., C\u00f4t\u00e9, E., Lessard, O., Gibeault, C., Bocti, C., and Roberge, P. (2018). Patterns of Benzodiazepines Use in Primary Care Adults with Anxiety Disorders. Helyon, 4.","DOI":"10.1016\/j.heliyon.2018.e00688"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Garakani, A., Murrough, J.W., Freire, R.C., Thom, R.P., Larkin, K., Buono, F.D., and Iosifescu, D.V. (2020). Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.595584"},{"key":"ref_19","first-page":"VE01","article-title":"Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond","volume":"9","author":"Sachdeva","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: Uses, Dangers, and Clinical Considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/neurolint13040062","article-title":"Anesthetic Considerations for Patients on Psychotropic Drug Therapies","volume":"13","author":"Harbell","year":"2021","journal-title":"Neurol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Li, Y., Ma, J., Jin, Y., Li, N., Zheng, R., Mu, W., Wang, J., Si, J.H., Chen, J., and Shang, H.C. (2020). Benzodiazepines for Treatment of Patients with Delirium Excluding Those Who Are Cared for in an Intensive Care Unit. Cochrane Database Syst. Rev., 2.","DOI":"10.1002\/14651858.CD012670.pub2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1176\/appi.ps.54.10.1395","article-title":"Benzodiazepine Use and Abuse among Patients with Severe Mental Illness and Co-Occurring Substance Use Disorders","volume":"54","author":"Brunette","year":"2003","journal-title":"Psychiatr. Serv."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Guina, J., and Merrill, B. (2018). Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives. J. Clin. Med., 7.","DOI":"10.3390\/jcm7020017"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"(2023). By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2023 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults. J. Am. Geriatr. Soc., 71, 2052\u20132081.","DOI":"10.1111\/jgs.18372"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s12325-022-02055-y","article-title":"Surviving Benzodiazepines: A Patient\u2019s and Clinician\u2019s Perspectives","volume":"39","author":"Silvernail","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","article-title":"Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies","volume":"91","author":"Markota","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Filimonovic, J., Stevanovic, M., Gazibara, T., Saponjic, V., Dotlic, J., Simonovic, P., Vukajlovic, I., Stojanovic Tasic, M., Joksimovic, B., and Stosic, M. (2025). Utilization of Psychotropic Drugs in Serbia from 2006 to 2021: Patterns before and during the COVID-19 Pandemic. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0330749"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Samard\u017ei\u0107, J. (2022). Impact of the COVID-19 pandemic on consumption of anxiolytic drugs in Serbia: Analysis for 2019\u20132021. Intrinsic Act., 10.","DOI":"10.25006\/IA.10.S2-A1.8"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine Harm: How Can It Be Reduced?: Benzodiazepine Harm: How Can It Be Reduced?","volume":"77","author":"Lader","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.psychres.2016.01.040","article-title":"Continuation and Discontinuation of Benzodiazepine Prescriptions: A Cohort Study Based on a Large Claims Database in Japan","volume":"237","author":"Takeshima","year":"2016","journal-title":"Psychiatry Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","article-title":"Long-Term Use of Benzodiazepines: Definitions, Prevalence and Usage Patterns\u2014A Systematic Review of Register-Based Studies","volume":"30","author":"Kurko","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1007\/s11606-025-09499-2","article-title":"Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits","volume":"40","author":"Brunner","year":"2025","journal-title":"J. Gen. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wilson, D.L., Fernandes, D., Adkins, L.E., Bantad, A., Copacia, C., Dharma, N., Huang, P.-L., Joseph, A., and Park, T.W. (2023). Deprescribing Strategies for Opioids and Benzodiazepines with Emphasis on Concurrent Use: A Scoping Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051788"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Carr, F., Gruneir, A., Chow, J., and Triscott, J. (2026). Deprescribing Benzodiazepines across Different Healthcare Settings: A Quality Improvement Initiative. BMJ Open Qual., 15.","DOI":"10.1136\/bmjoq-2025-003705"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003495-199448010-00004","article-title":"Guidelines for the Rational Use of Benzodiazepines. When and What to Use","volume":"48","author":"Ashton","year":"1994","journal-title":"Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YIC.0000000000000316","article-title":"Understanding the Effects of Chronic Benzodiazepine Use in Depression: A Focus on Neuropharmacology: A Focus on Neuropharmacology","volume":"35","author":"Lim","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_38","unstructured":"Mari\u0107, N., Kosti\u0107, M., Samard\u017ei\u0107, J., Pejovi\u0107 Nikoli\u0107, S., and Vukovi\u0107, O. (2020). Preporuke za Odgovornu Upotrebu Benzodiazepina u Za\u0161titi Du\u0161evnog Zdravlja, Institut za Mentalno Zdravlje."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Vinkers, C.H., and Olivier, B. (2012). Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators?. Adv. Pharmacol. Sci., 2012.","DOI":"10.1155\/2012\/416864"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1592\/phco.24.13.1177.38089","article-title":"Paradoxical Reactions to Benzodiazepines: Literature Review and Treatment Options","volume":"24","author":"Mancuso","year":"2004","journal-title":"Pharmacotherapy"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chapoutot, M., Meloni, F., Peter-Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R., Nicolas, A., Higgins, S., and Bourgeois, A. (2025). A Narrative Review of Strategies for Discontinuing Long-Term Benzodiazepine Use and Methodological Recommendations: Is a Success Rate of Only One in Three Patients Sufficient?. J. Behav. Cogn. Ther., 35.","DOI":"10.1016\/j.jbct.2025.100533"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Guina, J., and Merrill, B. (2018). Benzodiazepines II: Waking up on Sedatives: Providing Optimal Care When Inheriting Benzodiazepine Prescriptions in Transfer Patients. J. Clin. Med., 7.","DOI":"10.3390\/jcm7020020"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ashkanani, F.Z., Rathbone, A.P., and Lindsey, L. (2023). The Role of Pharmacists in Deprescribing Benzodiazepines: A Scoping Review. Explor. Res. Clin. Soc. Pharm., 12.","DOI":"10.1016\/j.rcsop.2023.100328"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kaplan, K., and Hunsberger, H.C. (2023). Benzodiazepine-Induced Anterograde Amnesia: Detrimental Side Effect to Novel Study Tool. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1257030"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine Use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Imani, M.H., Imani, A.H., Saem, A., and Niksolat, M. (2025). Sedative-Hypnotic Drug Use and Risk of Falls and Fractures in Elderly Patients: A Cross-Sectional Study. BMC Geriatr., 25.","DOI":"10.1186\/s12877-025-06624-y"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40262-025-01494-4","article-title":"Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Moody, D.E. (2012). Drug Interactions with Benzodiazepines: Epidemiologic Correlates with Other CNS Depressants and in Vitro Correlates with Inhibitors and Inducers of Cytochrome P450 3A4. Handbook of Drug Interactions, Humana Press.","DOI":"10.1007\/978-1-61779-222-9_2"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/ADM.0000000000000513","article-title":"Prescribing of Opioids and Benzodiazepines among Patients with History of Overdose","volume":"13","author":"Griggs","year":"2019","journal-title":"J. Addict. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/SAR.S550775","article-title":"Benzodiazepine Use among Individuals with Opioid Use Disorder: A Narrative Review","volume":"16","author":"Liu","year":"2025","journal-title":"Subst. Abus. Rehabil."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Bharat, C., Gisev, N., Barbieri, S., Dobbins, T., Larney, S., Buizen, L., and Degenhardt, L. (2024). Prescription Opioid Use among People with Opioid Dependence and Concurrent Benzodiazepine and Gabapentinoid Exposure: An Analysis of Overdose and All-Cause Mortality. Int. J. Drug Policy, 123.","DOI":"10.1016\/j.drugpo.2023.104287"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","article-title":"The Epidemiology of Benzodiazepine Misuse: A Systematic Review","volume":"200","author":"Votaw","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gerlach, L.B., Zhang, L., Kim, H.M., Teno, J., and Maust, D.T. (2025). Benzodiazepine or Antipsychotic Use and Mortality Risk among Patients with Dementia in Hospice Care. JAMA Netw. Open, 8.","DOI":"10.1001\/jamanetworkopen.2025.37551"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.18773\/austprescr.2019.011","article-title":"Combination Psychotropic Medicine Use in Older Adults and Risk of Hip Fracture","volume":"42","author":"Westaway","year":"2019","journal-title":"Aust. Prescr."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Oldenhof, E., Anderson-Wurf, J., Hall, K., and Staiger, P.K. (2019). Beyond Prescriptions Monitoring Programs: The Importance of Having the Conversation about Benzodiazepine Use. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122143"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of Benzodiazepine Dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/10\/1392\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:14:15Z","timestamp":1779509655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/14\/10\/1392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["healthcare14101392"],"URL":"https:\/\/doi.org\/10.3390\/healthcare14101392","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}